CL2014003078A1 - Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso. - Google Patents

Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso.

Info

Publication number
CL2014003078A1
CL2014003078A1 CL2014003078A CL2014003078A CL2014003078A1 CL 2014003078 A1 CL2014003078 A1 CL 2014003078A1 CL 2014003078 A CL2014003078 A CL 2014003078A CL 2014003078 A CL2014003078 A CL 2014003078A CL 2014003078 A1 CL2014003078 A1 CL 2014003078A1
Authority
CL
Chile
Prior art keywords
fgf21
homodimer
encodes
protein
produce
Prior art date
Application number
CL2014003078A
Other languages
English (en)
Spanish (es)
Inventor
Craig Duane Dickinson
David Albert Driver
Malgorzata Donata Gonciarz
Ryan James Darling
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670814&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2014003078A1 publication Critical patent/CL2014003078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y10S530/814—Cellulose or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2014003078A 2012-06-11 2014-11-13 Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso. CL2014003078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658104P 2012-06-11 2012-06-11
US201361777386P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
CL2014003078A1 true CL2014003078A1 (es) 2015-02-27

Family

ID=48670814

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003078A CL2014003078A1 (es) 2012-06-11 2014-11-13 Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso.

Country Status (24)

Country Link
US (2) US8741841B2 (instruction)
EP (1) EP2858662B1 (instruction)
JP (1) JP6182600B2 (instruction)
KR (1) KR20150006060A (instruction)
CN (1) CN104394882B (instruction)
AR (1) AR091216A1 (instruction)
AU (1) AU2013274638A1 (instruction)
BR (1) BR112014029966A2 (instruction)
CA (1) CA2871145A1 (instruction)
CL (1) CL2014003078A1 (instruction)
CO (1) CO7151525A2 (instruction)
EA (1) EA201492053A1 (instruction)
EC (1) ECSP14030742A (instruction)
ES (1) ES2644787T3 (instruction)
HK (1) HK1203357A1 (instruction)
IL (1) IL235832A0 (instruction)
IN (1) IN2014MN02132A (instruction)
MX (1) MX2014015257A (instruction)
PE (1) PE20150201A1 (instruction)
PH (1) PH12014502766A1 (instruction)
SG (1) SG11201408095XA (instruction)
TN (1) TN2014000439A1 (instruction)
TW (1) TWI513705B (instruction)
WO (1) WO2013188181A1 (instruction)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CA2835607C (en) 2011-07-01 2021-07-20 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
ES2632078T3 (es) * 2012-06-11 2017-09-08 Eli Lilly And Company Variantes del factor de crecimiento de fibroblastos 21
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
KR102724421B1 (ko) 2012-12-27 2024-10-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CN105828878A (zh) 2013-10-28 2016-08-03 恩格姆生物制药公司 癌症模型及相关方法
LT3097122T (lt) 2014-01-24 2020-07-27 Ngm Biopharmaceuticals, Inc. Antikūnai, surišantys beta kloto domeną 2, ir jų panaudojimo būdai
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
EP3125921B1 (en) 2014-03-11 2020-07-08 Novartis AG Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy
EP3122776B1 (en) 2014-03-25 2021-04-28 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3155005A4 (en) 2014-06-16 2018-07-11 NGM Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
US10293026B2 (en) 2014-09-08 2019-05-21 Osaka University Agent for preventing or treating demyelinating disease
US10517929B2 (en) 2014-10-23 2019-12-31 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising FGF19 variants
PT3412302T (pt) 2014-10-24 2021-06-09 Bristol Myers Squibb Co Polipéptidos de fgf-21 modificados e utilizações dos mesmos
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US11638745B2 (en) 2015-05-20 2023-05-02 University of Pittsburgh—Of the Commonwealth Cvctom of Hierher Education Method to improve neurologic outcomes in temperature managed patients
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
KR102670157B1 (ko) 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
CA3003616C (en) 2015-11-09 2020-07-28 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN105348380B (zh) * 2015-12-28 2019-03-01 江苏康缘瑞翱生物医药科技有限公司 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
CA3042512A1 (en) * 2016-11-10 2018-05-17 Yuhan Corporation Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
ES3014984T3 (en) 2017-03-14 2025-04-28 Sunshine Lake Pharma Co Ltd Dual-target fusion proteins comprising the fc portion of an immunoglobulin
US11560416B2 (en) 2017-04-21 2023-01-24 Yuhan Corporation Method for producing dual function proteins and its derivatives
CN107385020A (zh) * 2017-06-23 2017-11-24 西安医学院 瘦素在人重组fgf21蛋白活性检测中的应用
KR20200051706A (ko) 2017-09-08 2020-05-13 브리스톨-마이어스 스큅 컴퍼니 비알콜성 지방간염 (nash)을 치료하는 방법에 사용하기 위한 변형된 섬유모세포 성장 인자 21 (fgf-21)
EP3749683A4 (en) 2018-02-08 2022-03-16 Sunshine Lake Pharma Co., Ltd. FGF21 VARIANT, FUSION PROTEIN AND USE THEREOF
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
CN111195234B (zh) * 2018-11-16 2022-08-26 鲁南制药集团股份有限公司 一种重组FGF21-Fc融合蛋白冻干粉制剂
EP3935075A4 (en) * 2019-03-05 2023-01-18 Sunshine Lake Pharma Co., Ltd. POLYPEPTIDIC MOLECULE AND ITS APPLICATION
SG11202111570TA (en) * 2019-04-23 2021-11-29 Lg Chemical Ltd Fusion polypeptide comprising fc region of immunoglobulin and gdf15
US20230346957A1 (en) 2020-01-08 2023-11-02 Bristol-Myers Squibb Company Fgf-21 conjugate formulations
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4192495A1 (en) 2020-08-07 2023-06-14 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
KR20220021207A (ko) 2020-08-13 2022-02-22 주식회사 나이벡 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물
KR102495299B1 (ko) * 2020-11-03 2023-02-06 토드제약 주식회사 Fgf21의 열탄력성을 이용한 fgf21 생산 방법
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
KR102631925B1 (ko) * 2021-06-10 2024-02-01 토드제약 주식회사 신규 fgf21 변이체 개발 및 이의 생산기법과 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1702067A1 (en) 2003-12-10 2006-09-20 Eli Lilly And Company Muteins of fibroblast growth factor 21
PL1751184T3 (pl) * 2004-05-13 2010-02-26 Lilly Co Eli Białka fuzyjne FGF-21
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
JOP20190083A1 (ar) * 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
CH699521A2 (de) 2008-09-09 2010-03-15 Rotorcraft Ag Streckwerk für eine Strickmaschine.
UA105016C2 (uk) 2008-10-10 2014-04-10 Амген Інк. Fgf21 мутанти і їх застосування
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
WO2010084169A2 (en) 2009-01-23 2010-07-29 Novo Nordisk A/S Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
PL3248610T3 (pl) 2009-05-05 2024-04-02 Amgen Inc. Mutanty fgf21 i ich zastosowania
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2011154349A2 (en) * 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
AR087973A1 (es) 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質

Also Published As

Publication number Publication date
US20130330336A1 (en) 2013-12-12
PH12014502766A1 (en) 2015-02-09
MX2014015257A (es) 2015-03-05
CN104394882B (zh) 2016-06-22
US20140228282A1 (en) 2014-08-14
WO2013188181A1 (en) 2013-12-19
ES2644787T3 (es) 2017-11-30
CN104394882A (zh) 2015-03-04
ECSP14030742A (es) 2015-09-30
EP2858662A1 (en) 2015-04-15
IN2014MN02132A (instruction) 2015-09-11
AU2013274638A1 (en) 2014-11-06
TW201408693A (zh) 2014-03-01
CO7151525A2 (es) 2014-12-29
CA2871145A1 (en) 2013-12-19
AR091216A1 (es) 2015-01-21
EP2858662B1 (en) 2017-08-09
JP2015527974A (ja) 2015-09-24
KR20150006060A (ko) 2015-01-15
US8741841B2 (en) 2014-06-03
IL235832A0 (en) 2015-01-29
BR112014029966A2 (pt) 2017-09-12
SG11201408095XA (en) 2015-01-29
US8927492B2 (en) 2015-01-06
JP6182600B2 (ja) 2017-08-16
EA201492053A1 (ru) 2015-02-27
HK1203357A1 (en) 2015-10-30
TWI513705B (zh) 2015-12-21
PE20150201A1 (es) 2015-02-19
TN2014000439A1 (en) 2016-03-30

Similar Documents

Publication Publication Date Title
CL2014003078A1 (es) Homodimero de una proteínas del factor 21 de crecimiento del fibroblasto (fgf21); molecula de adn que la codifica; proceso para producirla y sus uso.
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2020009401A (es) Ligadores de nucleótidos modificados.
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
DK3708668T3 (da) Kunstigt nukleinsyremolekyle til forbedret proteinudtrykkelse
EA201690671A1 (ru) Пустотные изделия и композиционные материалы, способы их производства и применения
BR112014027544A2 (pt) composição cosmética, processo cosmético e uso cosmético.
EP3426270A4 (en) A TRANSITIONAL COMMENSAL MICROORGANISM TO IMPROVE INTESTINAL HEALTH
EA201171148A1 (ru) Антитело-антагонист, специфичное для гетеродимера альфа-4-бета-7
DK2831241T3 (da) Kunstige nukleinsyremolekyler til forbedret protein- eller peptidekspression.
MX375524B (es) Anticuerpos anti-axl.
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
MX379312B (es) Anticuerpos especificos para fcrn.
DK2938740T3 (da) Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
DOP2013000178A (es) Tratamiento de la osteoartritis y del dolor
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
EA201391041A1 (ru) Растворимые в воде мембранные белки и способы их получения и применения
BR112014026815A2 (pt) composição cosmética, processo cosmético e uso de uma composição cosmética
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
CR20150554A (es) Elementos regulatorios de planta y sus usos
BR112015010525A2 (pt) processo para alisamento de fibras de queratina, uso de uma composição e composição cosmética.
CL2011003312A1 (es) Quimera de adn polimerasa que comprende una secuencia de adn polimerasa del tipo fi29, una secuencia conectora y una secuencia hélice-gancho hélice (hhh); uso de la quimera para replicacion, amplificacion o secuenciacion de adn molde; metodo de replicacion, amplificacion o secuenciacion de un adn molde.
EA201700057A1 (ru) Терапевтическое применение белка, связывающегося с рецепторами нейротрофинов p75ntr
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.